Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

MK-8507 Extended Multiple Dose Study

This research study is testing a new medicine called MK-8507 for people with HIV-1 infection. It’s a very early-stage study, often called a Phase 1 study, which means researchers are mainly checking how the new medicine behaves in the body and if it’s safe when people take it more than once. They want to understand things like how much of the medicine gets into the blood and how long it stays there. The study is open to adults aged 18 and older, both men and women. There’s no detailed information yet about precisely what the medicine does or how it will be given, but the main goal is to gather basic information about its safety and effects in people.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC

Enrolment target

Start

02 Oct 2023

HIV-1 infection

What is this study about?

This study is centered around a new experimental medicine, known by its code name MK-8507. It's designed for people living with HIV-1, the most common type of Human Immunodeficiency Virus. This virus attacks the body's immune system, making it harder to fight off infections. The goal of new medicines is to help manage the virus and improve the health of those affected.

This particular study is in its very early stages – it's a 'Human Pharmacology', or Phase 1, study. This means researchers are primarily focusing on understanding basic information about MK-8507. They want to see how the medicine acts in the human body, for example, how it's absorbed, distributed, processed, and eventually leaves the body. A key part of this initial research is also to carefully check for any side effects and to make sure the medicine is safe when people take it multiple times.

Understanding how a new medicine works in the body and its initial safety is a crucial step before it can be studied in larger groups of people. Insights from this study will help researchers decide if MK-8507 is promising enough to move on to further, more advanced research. Ultimately, this work contributes to the ongoing effort to find better treatments for HIV-1.

Key takeaways

This study is testing a new medicine (MK-8507) for HIV-1 infection.
It's an early-stage study, checking safety and how the medicine works in the body.
Open to adults aged 18 and over, both men and women.
You would receive careful medical monitoring.
There are potential benefits (access to new medicine) and risks (unknown side effects).
You can stop participating at any time.

Who may be eligible?

This study is open to adults who are 18 years old or older. Both men and women are welcome to take part in this research.

While the basic requirements are quite broad, it's important to remember that there will be other specific rules about who can and cannot join. These rules are put in place to ensure patient safety and to make sure the study results are clear and reliable.

For example, doctors might need to check your overall health, any other medicines you take, or specific details about your HIV-1 infection. You would need to discuss all these details with the study team to see if you are a good fit.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have HIV-1 infection?
Are you willing to attend regular clinic visits?
Are you happy to take a new experimental medicine?
Are you able to understand and sign consent forms?

Answer every question to see your result.

What does participation involve?

As this is an early-stage study, taking part would likely involve several visits to a clinic. During these visits, you might have blood samples taken, undergo physical examinations, and have other tests to monitor your health and how the medicine is affecting your body. You would receive doses of the new medicine, MK-8507, possibly over several days or weeks. The study team would carefully explain when and how you need to take the medicine. You would also have follow-up appointments after you stop taking the medicine to make sure you are doing well. The overall time you would be involved in the study could range from several weeks to a few months, depending on the exact design.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study is that you would be among the first to try a new medicine that might one day help treat HIV-1. You would also receive careful medical attention and monitoring throughout the study. However, because MK-8507 is a new medicine, there is a risk of unknown side effects or that it might not work as hoped. The study team will explain all known risks. Remember, you can always choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Belgium

Common questions

What is HIV-1 infection?

HIV-1 is a virus that can weaken your body's immune system, making it harder to fight off illnesses.

What does a 'Phase 1' study mean?

It means this is a very early study to check if a new medicine is safe and how it works in the human body for the first time.

What is MK-8507?

MK-8507 is the code name for a new experimental medicine being tested for HIV-1 infection.

Do I have to pay to join the study?

No, you do not have to pay to participate in a clinical study. All study-related care and medication are provided free of charge.

Can I continue with my current HIV treatment if I join?

This would need to be discussed with the study doctors. Sometimes, current treatments must be paused or changed for the study, but the team will explain this fully.